VPT:CC - Ventripoint to Present its AI-enhanced Cardiac Ultrasound Technology to B.C. and Canadian Health Care Leaders at The Data Effect
(TheNewswire)
Toronto, Ontario – TheNewswire - June 24, 2024 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"),(TSXV:VPT ) ; ( OTC:VPTDF) has beenselected to present its AI-enhanced cardiac ultrasound technology,which generates MRI-quality cardiac measurements in minutes, tohealth-care leaders at The Data Effect on June 25 th in Vancouver.
CEO Hugh MacNaught will be on the panel Accelerating AI Startupsin Canadian Health Care , which exploresapplications of AI and digital health with global impact.
He is being joined on this panel at The DataEffect by other health care leaders,including: Maryam Sadeghi PhD, CEO & Co-Founder of MetaOptima;Lloyd Jura, a Professor specializing in AI and cybersecurity at NewYork Institute of Technology; Tiffany Chiu, AbCellera’sVice-President of Communications; and the Vancouver-based innovatorDr. Alexandra T Greenhill, CEO of CareTeam Technologies.
“This is an important forum to meet the innovators as well as thehealth care and hospital thought leaders who are at the lead ofbringing new approaches to data and AI to provincial health caresystems,” said MacNaught. “We are delighted to have been invitedto The Data Effect, as we introduce Ventripoint innovations tohospitals around Canada and the world.”
Ventripoint’s VMS+ easily interfaces with all major brands ofechocardiography machines and transforms 2D ultrasound scans into 3Dimages of all four chambers of the heart more rapidly and at lessexpense than cardiac MRI. VMS+ has received clearance by FDA, and islicensed for sale by Health Canada and regulators in the UK and EU. Itis now being used in leading hospitals in Canada, the US, Germany andthe UK.
The Data Effect has been gathering Canada’s health care leaderstogether for more than a decade, to highlight technologies and ideasto improve health care for caregivers and patients. The Vancouver DataEffect, part of an ongoing series looking at AI and data in healthcare and other sectors, is being attended by more than 125 health careleaders.
The focus of the Vancouver conference is on howCanadian technologies, data and AI can advance health care solutionsand patient care. It is part of The Data Effect‘s stated mission to bring together leaders and technologies to“explore how new approaches in health data stewardship and AI – incombination with innovations in health campus design and life scienceresearch – can drive better health services in Canada and build ourglobal profile.“
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.